Novartis News Archives

The focus of AstraZeneca 's earnings report illustrates the nature of polar opposites with one-time gains and new drugs.

Human Genome Sciences Inc. narrowed its third-quarter losses by a third, partly by increasing its revenue by 61 percent.

Idenix Pharmaceuticals Inc. says its partner Novartis AG will not move ahead with optioning a license to a potential hepatitis C drug.

Drugmakers say they are on track to deliver as much H1N1 swine flu vaccine to the United States as they promised, despite concerns over production.

Swiss drugmaker Novartis AG is on track to deliver pandemic H1N1 swine flu vaccine to the United States in line with its commitments, despite low yields of the initial seed virus, it said on Thursday.

Novartis announced today the completion of the new 1 megawatt solar array near its Vacaville biopharmaceutical site.

Swiss pharmaceutical giants Roche and Novartis are spending millions of dollars in an effort to influence United States politicians tackling health care reform.

Novartis has received a Complete Response letter from the US Food and Drug Administration as part of the US regulatory review for QAB149 , an investigational once-daily bronchodilator for the treatment of adult patients with chronic obstructive pulmonary disease .

Drug maker Novartis AG has posted a 1 percent increase in third-quarter net profit driven by strong sales from its pharmaceuticals division.

Novartis AG, /quotes/comstock/13*!nvs /quotes/nls/nvs [ch:novn] the Basel health-care giant, reported clinical-trial progress with two drugs.

Novartis has lots of moving parts, making it tricky to analyze, but it looks to me like the overall picture is pretty healthy.

Swine flu vaccine supplies in the U.S. are being hindered by production delays at two drugmakers, and GlaxoSmithKline Plca s failure to gain regulatory approval for its product, a government official said.

Amazon.com Inc. is slated to give its third-quarter report after the market close on Thursday.

Novartis AG raised its 2009 sales forecast as doctors prescribed more of the Gleevec cancer medicine and new treatments for eye disease and brittle bones.

Strong underlying growth in first nine months of 2009 from healthcare portfolio: Net sales of USD 31.3 billion rise 8% in local currencies , led by double-digit expansion in Pharmaceuticals Operating income of USD 7.3 billion up 1%, but advances 11% in constant currencies and excluding exceptional items Net income of USD 6.1 billion down 8% due to ...

Drugmakers on Thursday mostly posted improved third-quarter profits by keeping costs down, as generic competition, the global recession and unfavorable currency exchange rates generally hurt sales.

Novartis, which develops vaccines at its Cambridge lab, expects to generate $1.2 billion from its swine flu vaccine.

Nestle SA, the world's biggest food and drink company, said Thursday that sales for the first nine months fell 2.2 percent as the strong Swiss franc and weakened demand hurt overall performance.

Drug maker Novartis AG posted a 1 percent increase in third-quarter net profit driven by strong sales from its pharmaceuticals division.

Swiss drug maker Novartis AG recently noted its FTY720 oral drug to treat multiple sclerosis reduced both relapses and disability progression.

QLT Inc. shares fell for the second day in a row Tuesday after the company said it will have exclusive rights to sell and market its Visudyne treatment for age-related blindness in the United States starting next year.

Canadian biotechnology company QLT Inc. said Monday it will have all U.S. rights to the eye drug Visudyne after reworking a marketing agreement with Novartis AG.

Based on the aggregated intelligence of 140,000-plus investors participating in Motley Fool CAPS , the Fool's free investing community, Swiss pharmaceutical giant Novartis has earned a coveted five-star ranking .

A trial is under way in a Montana woman's lawsuit against Swiss drug maker Novartis Pharmaceuticals Corp., and attorneys say the verdict could have national significance.

Vancouver - Published on Monday, Oct. 19, 2009 8:22AM EDT Last updated on Monday, Oct.

Human Genome Sciences Inc. has reaped the rewards of recent laboratory success, earning a $75 million milestone payment from development partner Novartis AG for bringing its treatment for chronic hepatitis C to the edge of regulatory approval.

Swiss drugmaker Novartis AG said the U.S. Food and Drug Administration had requested more information on dosing proposed for its drug for "smoker's lung," or chronic obstructive pulmonary disease.

Acorda Therapeutics illustrates why investing in small biotech companies requires nerves of steel.

The Alabama Supreme Court today overturned a jury verdict against Novartis Pharmaceuticals Corporation , and directed entry of judgment in favor of NPC.

Swine flu vaccine production is taking longer than expected, delaying the biggest U.S. influenza prevention program just as disease rates reached their highest level, U.S. health officials reported.

According to Jimenez, head of Novartis' pharmaceuticals division, the company will follow the example of consumer goods companies such as US food maker HJ Heinz .

Novartis AG bought development and marketing rights to Vanda Pharmaceuticals Inc.'s schizophrenia treatment Fanapt in the U.S. and Canada for an initial payment of US$200 million.

In the biotech version of what goes around, comes around, Novartis AG will market Vanda Pharmaceuticals ' schizophrenia drug in the United States and Canada, which would net royalty revenue for South San Francisco's Titan Pharmaceuticals Inc.

Irish drugmaker Shire PLC said Tuesday it settled patent lawsuits against Novartis AG's Sandoz unit, which was trying to market a generic version of Shire's attention deficit hyperactivity disorder drug Adderall XR.

Novartis Pharma AG said Monday it has agreed to pay Vanda Pharmaceuticals Inc. up to $465 million to gain exclusive rights to sell Vanda's schizophrenia drug Fanapt in the U.S. and Canada.

Locus Pharmaceuticals entered into a discovery research collaboration Friday with Novartis .

An interview with Daniel Vasella, chairman and CEO of Novartis. Daniel Vasella In an industry often vilified for putting profits before patients, Daniel Vasella, chairman and chief executive officer of Novartis , the $40 billion pharmaceutical company headquartered in Basel, Switzerland, sits in a special spotlight.

Given the overdose of media coverage of the swine flu virus, there are a couple of points not being discussed: 1.) We keep hearing that clinical trials are underway -- but where? And by who? And how many people are getting tested? There are five private companies manufacturing the virus, and each is doing their own tests.

The CEOs of AstraZeneca, Novartis and Schering-Plough shared their views on healthcare reform at a Cleveland Clinic debate the other day but more interesting was what they didn't say.

Swiss drugmaker Novartis AG said Thursday it bought worldwide marketing rights to an antibiotic that is being developed to treat infections caused by drug-resistant bacteria, potentially including the "superbug" MRSA.

The whole world seems to be fixated on the economy and the H1N1 Swine Flu. News reports today that the first shipments of the nasal version of the vaccine, manufactured by MedImmune a unit of AstraZeneca, will begin today pushed me to find out if there might be an investing play in this fear.

Momenta Pharma presented at the 2009 UBS Global Life Sciences Conference about two weeks ago and outlined several key developments for t he compa ny, including an update on the FDA status for M-Enoxaparin. In late September, t he compa ny raised net proceeds of approximately $46.7 million through a public offering of 4.6 million shares of common at ...

The amazing thing about this market is that there are so many cheap stocks. The problem with this market is that there are so many companies that could really blow up on investors.

BeaconEquity.com announces an investment report featuring Talecris Biotherapeutics Holding Corp.

The European Medicines Agency recommended that Baxter's Celvapan be granted a marketing authorization in a statement issued on Friday.

Walgreen's pharmacy manager, Whitney Workman injects a customer with the seasonal flu vaccine in Columbia, S.C. The drugstore operators began their seasonal flu shots campaigns several weeks early this year.

Seven Summits Research issues PriceWatch Alerts for ORCL, SLB, AET, NVS, and AMSC.